Consensus Verastem, Inc.

Stocks

VSTM

US92337C2035

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 11:30:18 24/09/26 pm AEST			5-day change	1st Jan Change
8.125 ^USD	-0.67%		+11.75%	+5.96%

19/09	Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says	MT
17/09	Wolfe Research Initiates Verastem at Outperform	MT

Evolution of the Average Target: Verastem, Inc.

Evolution of the Target Price: Verastem, Inc.

Changes in Analyst Recommendations: Verastem, Inc.

50987a57.R2HDHWP-7F_nK1k_3UtJgMWQ3FjvBnAY8P2kMysKvoA.PQqORFK4gxKvSTd2sT4c9YHzkmqYPycvpbLLXHxB9uF3L5lYJY_ZbrNsKg~5f47decfc4644aa745da2538a0f4478e

Analysts' recommendations: Verastem, Inc.

19/09	Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says	MT
17/09	Wolfe Research Initiates Verastem at Outperform	MT
11/08	Mizuho Adjusts Price Target on Verastem to $13 From $14, Keeps Outperform Rating	MT
07/07	RBC Capital Adjusts Verastem Price Target to $14 From $15, Maintains Outperform Rating	MT
25/06	Verastem's VS-7375 Update Reiterates Potential in US Patients, RBC Says	MT
14/05	Mizuho Adjusts Price Target on Verastem to $14 From $16, Maintains Outperform Rating	MT
30/04	Mizuho Securities Keeps Verastem Price Target to $16, Maintains Outperform Rating	MT
30/04	Mizuho Securities Adjusts Verastem Price Target to $16 From $18, Maintains Outperform Rating	MT
08/01	RBC Raises Price Target on Verastem to $15 From $14, Keeps Outperform, Speculative Risk	MT
06/11	RBC Capital Adjusts Verastem Price Target to $14 From $13, Maintains Outperform Rating	MT
19/10/25	Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma	CI
26/08/25	B. Riley Raises Price Target on Verastem to $16 From $13, Keeps Buy Rating	MT
16/08/25	Mizuho Securities Cuts Price Target on Verastem to $14 From $16, Maintains Outperform Rating	MT
08/08/25	RBC Raises Price Target on Verastem to $13 From $12, Keeps Outperform, Speculative Risk	MT
25/06/25	RBC Cuts Price Target on Verastem to $12 From $16, Keeps Outperform, Speculative Risk	MT
10/05/25	B. Riley Adjusts Verastem Price Target to $13 From $12, Maintains Buy Rating	MT
10/05/25	Mizuho Adjusts Price Target on Verastem to $16 From $8, Maintains Outperform Rating	MT
09/05/25	RBC Raises Price Target on Verastem to $16 From $14, Keeps Outperform, Speculative Risk	MT
28/04/25	B. Riley Adjusts Verastem Price Target to $12 From $9, Maintains Buy Rating	MT
10/04/25	Jefferies Initiates Verastem at Buy With $15 Price Target	MT
09/04/25	Mizuho Securities Adjusts Verastem Price Target to $8 From $9, Maintains Outperform Rating	MT
21/03/25	RBC Cuts Price Target on Verastem to $14 From $16, Maintains Outperform Rating	MT
01/02/25	B. Riley Adjusts Verastem's Price Target to $9 From $7, Maintains Buy Rating	MT
07/01/25	RBC Raises Price Target on Verastem to $16 From $13, Keeps Outperform, Speculative Risk	MT
31/12/24	BTIG Raises Price Target on Verastem to $20 From $13, Keeps Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	VERASTEM, INC.					+79.3%
	WUXI APPTEC CO., LTD.					+11.38%
	ARGENX SE					+23.5%
	INSMED INCORPORATED					+68.62%
	BIONTECH SE					+19.14%
	GENMAB A/S					+0.49%
	PHARMAESSENTIA CORPORATION					+18.92%
	EXELIXIS, INC.					-5.36%
	SUMMIT THERAPEUTICS INC.					+76.86%
	MADRIGAL PHARMACEUTICALS, INC.					+32.71%
	Average					+32.56%
	Weighted average by Cap.					+23.71%